Potential utilization of bystander/abscopal-mediated signal transduction events in the treatment of solid tumors

Current Signal Transduction Therapy

Volumn 2, Issue 2, 2007, Pages 129-143

  Peters, Matthew E ^a,b   Shareef, Mohammed M ^a   Gupta, Seema ^a   Zagurovskaya Sultanov, Marianna ^a   Kadhim, Munira ^c   Mohiuddin, Mohammed ^d   Ahmed, Mansoor M ^a,d  

^a WEIS CENTER FOR RESEARCH   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d FOX CHASE CANCER CENTER   (United States)

Author keywords

Abscopal; Bystander; Cancer therapeutics; Carcinogenesis; Radiation; Signal transduction

Indexed keywords

ADENOVIRUS VECTOR; CARMUSTINE; CLUSTERIN; CYCLOPHOSPHAMIDE; CYTARABINE; EARLY GROWTH RESPONSE FACTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; FAS LIGAND; FLT3 LIGAND; FLUDARABINE PHOSPHATE; GANCICLOVIR; GAP JUNCTION PROTEIN; GEMCITABINE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; IRINOTECAN; MITOMYCIN C; MYC PROTEIN; NUCLEAR RECEPTOR NUR77; NUCLEIC ACID; PROTEIN BAX; PROTEIN P53; RETINOIC ACID; SINGLET OXYGEN; SOMATOMEDIN C; THYMIDINE KINASE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG;

ALPHA RADIATION; ANTISENSE THERAPY; APOPTOSIS; BLOOD BRAIN BARRIER; BYSTANDER EFFECT; CANCER CELL; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURGERY; CELL DAMAGE; CELL SURVIVAL; CLINICAL TRIAL; DNA DAMAGE; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG RELEASE; GENE FUNCTION; GENETIC CODE; GENETIC STABILITY; HUMAN; IMMUNOMODULATION; IONIZING RADIATION; MALIGNANT TRANSFORMATION; METASTASIS POTENTIAL; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NONHUMAN; NONVIRAL GENE THERAPY; OVARY CARCINOMA; PANCREAS CANCER; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; RADIATION DOSE; RADIATION EXPOSURE; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STEM CELL GENE THERAPY; STEM CELL TRANSPLANTATION; SUICIDE GENE THERAPY; T LYMPHOCYTE ACTIVATION; UTERINE CERVIX CARCINOMA; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 34249284167     PISSN: 15743624     EISSN: None     Source Type: Journal    
DOI: 10.2174/157436207780619509     Document Type: Review

References (155)

1. Little JB. Genomic instability and bystander effects: A historical perspective. Oncogene 2003; 22: 6978-87.
2. Mothersill CE, Moriarty MJ, Seymour CB. Radiotherapy and the potential exploitation of bystander effects. Int J Radiat Oncol Biol Phys 2004; 58: 575-9.
3. Nikjoo H, Khvostunov IK. A theoretical approach to the role and critical issues associated with bystander effect in risk estimation. Hum Exp Toxicol 2004; 23: 81-6.
4. Waldren CA. Classical radiation biology dogma, bystander effects and paradigm shifts. Hum Exp Toxicol 2004; 23: 95-100.
5. Camphausen K, Moses MA, Menard C, et al. Radiation abscopad antitumor effect is mediated through p53. Cancer Res 2003; 63: 1990-3.
6. Kaminski JM, Shinohara E, Summers JB, Niermann KJ, Morimoto A, Brousal J. The controversial abscopal effect. Cancer Treat Rev 2005; 31: 159-72.
7. Sham RL. The abscopal effect and chronic lymphocytic leukemia. Am J Med 1995; 98: 307-8.
8. Nobler MP. The abscopal effect in malignant lymphoma and its relationship to lymphocyte circulation. Radiology 1969; 93: 410-2.
9. Kingsley DP. An interesting case of possible abscopal effect in malignant melanoma. Br J Radiol 1975; 48: 863-6.
10. Rees GJ, Ross CM. Abscopal regression following radiotherapy for adenocarcinoma. Br J Radiol 1983; 56: 63-6.
11. Moss RW. The war on cancer. In Townsend Letter for Doctors and Patients 2003.
12. Sawant SG, Zheng W, Hopkins KM, Randers-Pehrson G, Lieberman HB, Hall EJ. The radiation-induced bystander effect for clonogenic survival. Radiat Res 2002; 157: 361-4.
13. Nagasawa H, Little JB. Induction of sister chromatid exchanges by extremely low doses of alpha-particles. Cancer Res 1992; 52: 6394-6.
14. Azzam EI, de Toledo SM, Little JB. Stress signaling from irradiated to nonirradiated cells. Curr Cancer Drug Targets 2004; 4: 53-64.
15. Snyder AR. Review of radiation-induced bystander effects. Hum Exp Toxicol 2004; 23: 87-9.
16. Zhou H, Randers-Pehrson G, Waldren CA, Vannais D, Hall EJ, Hei TK. Induction of a bystander mutagenic effect of alpha particles in mammalian cells. Proc Natl Acad Sci USA 2000; 97: 2099-104.
17. Azzam EI, de Toledo SM, Little JB. Direct evidence for the participation of gap junction-mediated intercellular communication in the transmission of damage signals from alpha-particle irradiated to nonirradiated cells. Proc Natl Acad Sci USA 2001; 98: 473-8.
18. Mothersill C, Seymour CB, Cell-cell contact during gamma irradiation is not required to induce a bystander effect in normal human keratinocytes: Evidence for release during irradiation of a signal controlling survival into the medium. Radiat Res 1998; 149: 256-62.
19. Wright EG. Commentary on radiation-induced bystander effects. Hum Exp Toxicol 2004; 23: 91-4.
20. Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004; 58: 862-70.
21. Melief CJ. Tumor eradication by adoptive transfer of cytotoxic t lymphocytes. Adv Cancer Res 1992; 58: 143-75.
22. Chakravarty PK, Alfieri A, Thomas EK, et al. Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Res 1999; 59: 6028-32.
23. Mohiuddin M, Fujita. M, Reginc WF, Megooni AS, Ibbott GS, Ahmed MM. High-dose spatially-fractionated radiation (grid): A new paradigm in the management of advanced cancers. Int J Radiat Oncol Biol Phys 1999; 45: 721-7.
24. Coffey JC, Wang JH, Smith MJ, et al. Phosphoinositide 3-kinase accelerates postoperative tumor growth by inhibiting apoptosis and enhancing resistance to chemotherapy-induced apoptosis. Novel role for an old enemy. J Biol Chem 2005; 280: 20968-77.
25. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1: 149-53.
26. Pidgeon GP, Harmey JH, Kay E, Da Costa M, Redmond HP, Bouchier-Hayes DJ. The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease. Br J Cancer 1999; 81: 1311-7.
27. Gururangan S, Cokgor L, Rich JN, et al. Phase i study of gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro-oncol 2001; 3: 246-50.
28. Giese A, Kucinski T, Knepp U, et al. Pattern of recurrence following local chemotherapy with biodegradable carmustine (bcnu) implants in patients with glioblastoma. J Neurooncol 2004; 66: 351-60.
29. Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clin Pharmacokinet 2002; 41: 403-19.
30. Norris JS, Byer ML, Voelkel-Johnson C, Lowe SL, Rubinchik S, Dong JY. The use of fas ligand, trail and bax in gene therapy of prostate cancer. Curr Gene Ther 2001; 1: 123-36.
31. Fujiwara T, Kataoka M, Tanaka N. Adenovirus-mediated p53 gene therapy for human cancer. Mol Urol 2000; 4: 51-4.
32. Niculescu-Duvaz I, Springer CJ. Introduction to the background, principles, and state of the art in suicide gene therapy. Mol Biotechnol 2005; 30: 71-88.
33. Denny WA. Tumor-activated prodrugs-a new approach to cancer therapy. Cancer Invest 2004; 22: 604-19.
34. Huang G, Song Y, Xiao L, Lu Y, Zhang J, Chen W. The bystander effect of hsv-tk/gcv system on human cervical carcinoma cell line me 180. Sichuan Da Xue Xue Bao Yi Xue Ban 2003; 34: 51-4.
35. Pan X, Li Z, Xu G, et al. Adenoviral mediated suicide gene transfer in the treatment of pancreatic cancer. Clin Med J (Engl) 2002; 115: 1205-8.
36. Curiel DT, Michael, SI. Cancer gene therapy; "adenoviral-mediated delivery of herpes simplex virus thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovir. Cancer Biotechnology Weekly 1996; 22.
37. Kianmanesh AR, Perrin H, Paris Y, et al. A "distant" bystander effect of suicide gene therapy: Regression of nontransduced tumors together with a distant transduced tumor. Hum Gene Ther 1997; 8: 1807-14.
38. Hallahan DE, Mauceri HJ, Seung LP, et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1995; 1: 786-91.
39. Teh BS, Aguilar-Cordova E, Vlachaki MT, et al. Combining radiotherapy with gene therapy (from the bench to the bedside): A novel treatment strategy for prostate cancer. Oncologist 2002; 7: 458-66.
40. Staba MJ, Mauceri HJ, Kufe DW, Hallahan DE, Weichselbaum RR. Adenoviral tnf-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther 1998; 5: 293-300.
41. Dahle J, Angell-Petersen E, Steen HB, Moan J. Bystander effects in cell death induced by photodynamic treatment uva radiation and inhibitors of atp synthesis. Photochem Photobiol 2001; 73: 378-87.
42. Dahle J, Bagdonas S, Kaalhus O, Olsen G, Steen HB, Moan J. The bystander effect in photodynamic inactivation of cells. Biochim Biophys Acts, 2000; 1475: 273-80.
43. Dable J, Mikalsen SO, Rivedal E, Steen HB. Gap junctional intercellular communication is not a major mediator in the bystander effect in photodynamic, treatment of mdck ii cells. Radiat Res 2000; 154: 331-41.
44. Kokkinakis DM, Liu X, Chada S, et al. Modulation of gene expression in human central nervous system tumors under methionine deprivation-induced stress. Cancer Res 2004; 64: 7513-25.
45. Halpern BC, Clark BF, Hardy DN, Halpern RM, Smith RM. The effect of replacement of methionine by homocystine on survival of malignant and normal adult mammalian cells in culture. Proc Natl Acad Sci USA 1974; 71: 1133-6.
46. Jiang H, Su ZZ, Lin JJ, Goldstein NI, Young CS, Fisher PB. The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proc Natl Acad Sci USA 1996; 93: 9160-5.
47. Ellerhorst JA, Prieto VG, Ekmekcioglu S, et al. Loss of mda-7 expression with progression of melanoma. J Clin Oncol 2002; 20: 1069-74.
48. Sarkar D, Su ZZ, Lebedeva IV, et al. Mda-7 (il-24) mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the gadd family of genes by means of p38 mapk. Proc Natl Acad Sci USA 2002; 99: 10054-9.
49. Das A, Chendil D, Dey S, et al. Ionizing radiation down-regulates p53 protein in primary egr-1 -/- mouse embryonic fibroblast cells causing enhanced resistance to apoptosis. J Biol Chem 2001; 276: 3279-86.
50. Ahmed MM. Regulation of radiation-induced apoptosis by early growth response-1 gene in solid tumors. Curr Cancer Drug Targets 2004; 4: 43-52.
51. Fu M, Zhu X, Zhang J, et al. Egr-1 target genes in human endothelial cells identified by microarray analysis. Gene 2003; 315: 33-41.
52. Mizutani Y, Bonavida B, Koishihara Y, Akamatsu K, Ohsugi Y, Yoshida O. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(ii) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res 1995; 55: 590-6.
53. Miki S, Iwano M, Miki Y, et al. Interleukin-6 (il-6) Inactions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 1989; 250: 607-10.
54. Meng F, Yamagiwa Y, Taffetani S, Han J, Patel T. Interleukin-6 activates serum and glucocorticoid kinase via a p38 {alpha} mitogen activated protein kinase pathway. Am J Physiol Cell Physiol 2005; 289: C971-81.
55. Ishikawa H, Tsuyama N, Abroun S, et al. Interleukin-6, cd45 and the src-kinases in myeloma cell proliferation. Leuk Lymphoma 2003; 44: 1477-81.
56. Moran DM, Mayes N, Koniaris LG, Cahill PA, McKillop IH. Interleukin-6 inhibits cell proliferation in a rat model of hepatocellular carcinoma. Liver Int 2005; 25: 445-57.
57. Banerjee G, Gupta N, Kapoor A, Raman G. Uv induced bystander signaling leading to apoptosis. Cancer Lett 2005; 223: 275-94.
58. Klokov D, Criswell T, Leskov KS, Araki S, Mayo L, Boothman DA. Ir-inducible clusterin gene expression: A protein with potential roles in ionizing radiation-induced adaptive responses, genomic instability, and bystander effects. Mutat Res 2004; 568: 97-110.
59. Goldberg Z, Lehnert BE. Radiation-induced effects in unirradiated cells: A review and implications in cancer. Int J Oncol 2002; 21: 337-49.
60. Azzam EI, Little JB. The radiation-induced bystander effect: Evidence and significance. Hum Exp Toxicol 2004; 23: 61-5.
61. Iyer R, Lehnert BE, Svensson R. Factors underlying the cell growth-related bystander responses to alpha particles. Cancer Res 2000; 60: 1290-8.
62. Shao C, Furusawa, Y, Aoki M, Matsumoto H, Ando K. Nitric oxide-mediated bystander effect induced by heavy-ions in human salivary gland tumour cells. Int J Radiat Biol 2002; 78: 837-44.
63. Azzam EI, de Toledo SM, Raaphorst GP, Mitchel REJ. Radiation-induced radioresistance in a normal skin fibroblast cell line. In: Sugabara T, Sagan LA, Aoyama T, Eds. Low Dose Irradiation and Biological Defence Mechanisms, Elsevier, Amsterdam, 1992; pp. 291-294.
64. Valdes F, Murillo MM, Valverde AM, et al. Transforming growth factor-beta activates both pro-apoptotic and survival signals in fetal rat hepatocytes. Exp Cell Res 2004; 292: 209-18.
65. Shin I, Bakin AV, Rodeck U, Brunet A, Arteaga CL. Transforming growth factor beta enhances epithelial cell survival via akt-dependent regulation of fkhrll. Mod Biol Cell 2001; 12: 3328-39.
66. Vitals F, Pouyssegur J. Transforming growth factor betal (tgf-beta1) promotes endothelial cell survival during in vitro angiogencsis via an autocrine mechanism implicating tgf-alpha signaling. Mol Cell Biol 2001; 21: 7218-30.
67. Cuni S, Perez-Aciego P, Perez-Chacon G, et al. A sustained activation of pi3k/nf-kappab pathway is critical for the survival of chronic lymphocytic leukemia b cells. Leukemia 2004; 18: 1391-400.
68. Gleave ME, Miyake H, Zellweger T, et al. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/ testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. Urology 2001; 58: 39-49.
69. Yang CR, Leskov K, Hosley-Eberlein K, et al. Nuclear clusterin/ xip8, an xray-induced ku70-binding protein that signals cell death. Proc Natl Acad Sci USA 2000; 97: 5907-12.
70. Jin G, Howe PH. Transforming growth factor beta regulates clusterin gene expression via modulation of transcription factor c-fos. Eur J Biochem 1999; 263: 534-42.
71. Criswell T, Klokov D, Beman M, Lavik JP, Boothman DA. Repression of irinducible clusterin expression by the p53 tumor suppressor protein. Cancer Biol Ther 2003; 2: 372-80.
72. Kounnas MZ, Loukinova EB, Stefansson S, et al. Identification of glycoprotein 330 as an endocytie receptor for apolipoprotein j/ clusterin. J Biol Chem 1995; 270: 13070-5.
73. Bartl MM, Luckenbach T, Bergner O, Ullrich O, Koch-Brandt C. Multiple receptors mediate apoj-dependent clearance of cellular debris into nonprofessional phagocytes. Exp Cell Res 2001; 271: 130-41.
74. Matsumoto H, Hayashi S, Hatashita M, et al. Induction of radioresistance by a nitric oxide-mediated bystander effect. Radiat Res 2001; 155: 387-96.
75. Iyer R, Lehnert BE. Alpha-particle-induced increases in the radio-resistance of normal human bystander cells. Radiat Res 2002; 157: 3-7.
76. Iyer R, Lehnert BE. Low dose, low-let ionizing radiation-induced radioadapration and associated early responses in unirradiated cells. Mutat Res 2002; 503: 1-9.
77. Liebmann J, DeLuca AM, Coffin D, et al. In vivo radiation protection by nitric oxide modulation. Cancer Res 1994; 54: 3365-8.
78. Malyshev I, Manukhina EB, Mikoyan VD, Kubrina LN, Vanin AF. Nitric oxide is involved in heat-induced hsp70 accumulation. FEBS Left 1995; 370: 159-62.
79. Forrester K, Ambs S, Lupold SE, et al. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci USA 1996; 93: 2442-7.
80. Matsumoto H, Wang X, Ohnishi T. Binding between wild-type p53 and hsp72 accumulated after uv and gamma-ray irradiation. Cancer Lett 1995; 92: 127-33.
81. Ibuki Y, Hayashi A, Suzuki A, Goto R. Low-dose irradiation induces expression of heat shock protein 70 mma and thermo- and radio-resistance in myeloid leukemia cell line. Biol Pharm Bull 1998; 21: 434-9.
82. Ohtsubo T, Wang X, Takahashi A, et al. P53-dependent induction of waf1 by a low-ph culture condition in human glioblastoma cells. Cancer Res 1997; 57: 3910-3.
83. Gotlieb WH, Watson JM, Rezai A, Johnson M, Martinez-Maza O, Berek JS. Cytokine-induced modulation of tumor suppressor gene expression in ovarian cancer cells: Up-regulation of p53 gene expression and induction of apoptosis by tumor necrosis factor-alpha. Am J Obstet Gynecol 1994; 170: 1121-8; discussion 8-30.
84. Forstermann U, Gorsky LD, Pollock JS, Schmidt HH, Heller M, Murad F. Regional distribution of edrf/no-synthesizing enzyme(s) in rat brain. Biochem Biophys Res Commun 1990; 168: 727-32.
85. Gansauge S, Nussler AK, Beger HG, Gansauge F. Nitric oxide-induced apoptosis in human pancreatic carcinoma cell lines is associated with a g1-arrest and an increase ofthe cyclin-dependent kinase inhibitor p21 waf1/cip1. Cell Growth Differ 1998; 9: 611-7.
86. Azzam EI, de Toledo SM, Little JB. Oxidative metabolism, gap junctions and the ionizing radiation-induced bystander effect. Oncogene 2003; 22: 7050-7.
87. Shao C, Folkard M, Michael BD, Prise KM. Bystander signaling between glioma cells and fibroblasts targeted with counted particles. Int J Cancer 2005; 116: 45-51.
88. Shao C, Folkard M, Michael BD, Prise KM. Targeted cytoplasmic irradiation induces bystander responses. Proc Natl Acad Sci USA 2004; 101: 13495-500.
89. Dainiak N. Hematologic consequences of exposure to ionizing radiation. Exp Hematol 2002; 30: 513-28.
90. Van der Meeren A, Monti P, Vandamme M, Squiban C, Wysocki J, Griffiths N. Abdominal radiation exposure elicits inflammatory responses and abscopal effects in the lungs of mice. Radiat Res 2005; 163: 144-52.
91. Bevan MJ. Cross-priming for a secondary cytotoxic response to minor h antigens with h-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 1976; 143: 1283-8.
92. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting mhc class i-restricted tumor antigens. Science 1994; 264: 961-5.
93. Maraskovsky E, Brasel K, Teepe M, et al. Dramatic increase in the numbers of functionally mature dendritic cells in flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified. J Exp Med 1996; 184: 1953-62.
94. Albanese J, Dainiak N. Regulation of tnfrsf6 (fas) expression in ataxia telangiectasia cells by ionizing radiation. Radial Res 2000; 154: 616-24.
95. Zhang A, Wang Q, Han Z, et al. Relationship between the expression of connexin43 and bystander effect of suicide gene therapy in ovarian cancer. J Huazhong Univ Sci Technolog Med Sci 2004; 24: 476-9.
96. Lyng FM, Seymour CB, Mothersill C. Early events in the apoptotic cascade initiated in cells treated with medium from the progeny of irradiated cells. Radiat Prot Dosimetry 2002; 99: 169-72.
97. Nagar S, Morgan WF. The death-inducing effect and genomic instability. Radiat Res 2005; 163: 316-23.
98. Lyng FM, Seymour CB, Mothersill C. Initiation of apoptosis in cells exposed to medium from the progeny of irradiated cells: A possible mechanism for bystander-induced genomic instability? Radiat Res 2002; 157; 365-70.
99. Maguire P, Mothersill, C, Seymour C, Lyng FM. Medium from irradiated cells induces dose-dependent mitochondrial changes and bcl2 responses in unirradiated human keratinocytes. Radiat Res 2005; 163: 384-90.
100. Ikeda M, Furukawa H, Immarum H, et al. Surgery for gastric cancer increases plasma levels of vascular endothelial growth factor and von willebrand factor. Gastric Cancer 2002; 5: 137-41.
101. Maniwa Y, Okada M, Ishii N, Kiyooka K. Vascular endothelial growth factor increased by pulmonary surgery accelerates the growth of micrometastases in metastatic lung cancer. Chest 1998; 114: 1668-75.
102. Olcksowicz L, Dutcher JP. Adhesive receptors expressed by tumor cells and platelets: Novel targets for therapeutic anti-metastatic strategies. Med Oncol 1995; 12: 95-102.
103. Hong JS, Waud WR, Levasseur ON, et al. Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the escherichia coli purine nucleoside phosphorylasc gene. Cancer Res 2004; 64: 6610-5.
104. Manome Y. Cancer Gene Therapy; Gene Transfer Used to Sensitize Cancer Cells to Chemotherapy, In AIDS Weekly Plus 1996: Atlanta. 3.4.
105. Stefani AL, Barzon L, Castagliuolo I, et al. Systemic efficacy of combined suicide/cytokine gene therapy in a murine model of hepatocellular carcinoma. J Hepatol 2005; 42: 728-35.
106. Huang X, Lin T, Gu J, et al. Cell to cell contact required for bystander effect of the tnf-related apoptosis-inducing ligand (trail) gene. Int J Oncol 2003; 22: 1241-5.
107. van Dillen IJ, Mulder NH, Vaalburg W, de Vries EF, Hospers GA. Influence of the bystander effect on hsv-tk/gcv gene therapy. A review. Curr Gene Ther 2002; 2: 307-22.
108. Wilson DR. Viral-mediated gene transfer for cancer treatment. Curr Pharm Biotechnol 2002; 3: 151-64.
109. Reardon JE. Herpes simplex virus type 1 and human DNA polymerase interactions with 2′-deoxyguanosine 5′-triphosphate analogues. Kinetics of incorporation into DNA and induction of inhibition. J Biol Chem 1989; 264: 19039-44.
110. Matthews T, Boehme R. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis 1988; 10(Suppl 3): S490-4.
111. Thust R, Schacke M, Wutzler P. Cytogenetic genotoxicity of antiherpes virostatics in chinese hamster v79-e cells. I. Purine nucleoside analogues. Antiviral Res 1996; 31: 105-13.
112. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-2.
113. Wang AX, Huang HZ. [All-trans retinoic acid augments the bystander effect of herpes simplex virus thymidine kinase/ganciclovir system in the treatment of tongue carcinoma cell line]. Zhonghua Kou Qiang Yi Xue Za Zhi 2003; 38: 24-6.
114. Zhang X, Ren Z, Zuo J, et al. The effect of all-trans retinoic acid on gap junctional intercellular communication and connexin 43 gene expression in glioma cells. Chin Med Sci J 2002; 17: 22-6.
115. Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-83.
116. Bai S, Du L, Liu W, Whittle IR, He L. Tentative novel mechanism of the bystander effect in glioma gene therapy with hsv-dc/gcv system. Biochem Biophys Res Commun 1999; 259: 455-9.
117. Agard C, Ligeza C, Dupas B, et al. Immune-dependent distant bystander effect after adenovirus-mediated suicide gene transfer in a rat model of liver colorectal metastasis. Cancer Gene Ther 2001; 8: 128-36.
118. Chada S, Mhashilkar AM, Ramesh R, et al. Bystander activity of ad-mda7: Human mda-7 protein kills melanoma cells via an il-20 receptor-dependent but stat3-independent mechanism. Mol Ther 2004; 10: 1085-95.
119. Mhashilkar AM, Schrock RD, Hindi M, et al. Melanoma differentiation associated gene-7 (mda-7): A novel anti-tumor gene for cancer gene therapy. Mol Med 2001; 7: 271-82.
120. Caudell EG, Mumm JB, Poindexter N, et al. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory, activity and is designated il-24. J Immunol 2002; 168: 6041-6.
121. Nishikawa T, Ramesh R, Munshi A, Chada S, Meyn RE. Adenovirus-mediated mda-7 (il24) gene therapy suppresses angiogenesis and sensitizes nsclc xenograft tumors to radiation. Mol Ther 2004; 9: 818-28.
122. Ramesh R, Mhashilkar AM, Tanaka F, et al. Melanoma differentiation-associated gene 7/interleukin (il)-24 is a novel ligand that regulates angiogenesis via the il-22 receptor. Cancer Res 2003; 63: 5105-13.
123. Limoli CL, Giedzinski E. Induction of chromosomal instability by chronic oxidative stress. Neoplasia 2003; 5: 339-46.
124. Harrison LH, Jr., Schwarzenberger PO, Byrne PS, Marrogi AJ, Kolls JK, McCarthy KE. Gene-modified pa1-stk cells home to tumor sites in patients with malignant pleural mesothelioma. Ann Thorac Surg 2000; 70: 407-11.
125. Chhikara M, Huang H, Vlachaki MT, et al. Enhanced therapeutic effect of hsv-tk+gev gene therapy and ionizing radiation for prostate cancer. Mol Ther 2001; 3: 536-42.
126. Patterson AV, Saunders MP, Greco O. Prodrugs in genetic chemoradiotherapy. Curr Pharm Des 2003; 9: 2131-54.
127. Sharcef MM, Kokkinakis DM, Ahmed MM. Potential use of mda-7 as a biological adjuvant for radiation therapy. Cancer Biol Ther 2004; 3: 752-4.
128. Yacoub A, Mitchell C, Hong Y, et al. Mda-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells. Cancer Biol Ther 2004; 3: 739-51.
129. Preston RJ. Bystander effects, genomic instability, adaptive response, and cancer risk assessment for radiation and chemical exposures. Toxicol Appl Pharmacol 2005; 207: 550-6.
130. Liang L, Shao C, Deng L, Mendonca MS, Stambrook PJ, Tischfield JA. Radiation-induced genetic instability in vivo depends on p53 status. Mutat Res 2002; 502: 69-80.
131. Kadhim MA, Moore SR, Goodwin EH. Interrelationships amongst radiation-induced genomic instability, bystander effects, and the adaptive response. Mutat Res 2004; 568: 21-32.
132. Morgan WF. Non-targeted and delayed effects of exposure to ionizing radiation: Ii. Radiation-inducad genomic instability and bystander effects in vivo, clastogenic factors and transgenerational effects. Radiat Res 2003; 159: 581-96.
133. Sanchez-Ortiz RF, Tannir N, Ahrar K, Wood CG. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: An in situ tumor vaccine? J Urol 2003; 170: 178-9.
134. Tassone P, Neri P, Burger R, et al. Combination therapy with interleukin-6 receptor superantagonist sant7 and dexamethasone induces antitumor effects in a novel scid-hu in vivo model of human multiple myeloma. Clin Cancer Res 2005; 11: 4251-8.
135. Demartis A, Bernassola F, Savino R, Melino G, Ciliberto G. Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death. Cancer Res 1996; 56: 4213-8.
136. Dancey JE. Molecular targeting: PI3 kinase pathway. Ann Oncol 2004; 15(Suppl 4): iv233-9.
137. Huang S, Houghton PJ. Mechanisms of resistance to rapamycins. Drug Resist Updat 2001; 4: 378-91.
138. Workman P. Overview: Translating hsp90 biology into hsp90 drugs. Curr Cancer Drug Targets 2003; 3: 297-300.
139. Shi Y, Frankel A, Radvanyi LG, Penn LZ, Miller RG, Mills GB. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 1995; 55: 1982-8.
140. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M. Inhibitors of mtor reverse doxorubicin resistance conferred by pten status in prostate cancer cells. Cancer Res 2002; 62: 6141-5.
141. Hosoi H, Dilling MB, Liu LN, et al. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol 1998; 54: 815-24.
142. Gera JF, Mellinghoff IK, Shi Y, et al. Akt activity determines sensitivity to mammalian target of rapamycin (mtor) inhibitors by regulating cyclin d1 and c-myc expression. J Biol Chem 2004; 279: 2737-46.
143. Yamanaka K, Gleave ME, Hara I, Muramaki M, Miyake H. Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model. Mol Cancer Ther 2005; 4: 187-95.
144. Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, Gleave ME. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 2001; 3: 360-7.
145. Gleave M, Miyake H. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World J Urol 2005; 23: 38-46.
146. Biroccio A, D'Angelo C, Jansen B, Gleave ME, Zupi G. Antisense clusterin oligodeoxynucleotides increase the response of her-2 gene amplified breast cancer cells to trastuzumab. J Cell Physiol 2005; 204: 463-9.
147. Miyake H, Eto H, Hara I, So A, Li D, Gleave ME. Synergistic antitumor activity by combined treatment with gemcitabine and antisense oligode-oxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer kotcc-1 cells. J Urol 2004; 171: 2477-81.
148. Dubben HH, Thames HD, Bcck-Bornholdt HP. Tumor volume: A basic and specific response predictor in radiotherapy. Radiother Oncol 1998; 47: 167-74.
149. Sathishkumar S, Dey S, Meigooni AS, et al. The impact of tnf-alpha induction on therapeutic efficacy following high dose spatially fractionated (grid) radiation. Technol Cancer Res Treat 2002; 1: 141-7.
150. Sathishkumar S, Boyanovsky B, Karakashian AA, et al. Elevated sphingomyelinase activity and ceramide concentration in serum of patients undergoing high dose spatially fractionated radiation treatment: Implications for endothelial apoptosis. Cancer Biol Ther 2005; 4: 979-86.
151. Wei J, Blum S, Unger M, et al. Embryonic endothelial progenitor cells armed with a suicide gene target hypoxic lung metastases after intravenous delivery. Cancer Cell 2004; 5: 477-88.
152. Davidoff AM, Ng CY, Brown P, et al. Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin Cancer Res 2001; 7: 2870-9.
153. Lin P, Sankar S, Shan S, et al. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 1998; 9: 49-58.
154. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-ncgafive flk-1 mutant Nature 1994; 367: 576-9.
155. Mothersill C, Seymour CB. Bystander and delayed effects after fractionated radiation exposure. Radiat Res 2002; 158: 626-33.